Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05429268
Title Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Acronym firmMIND
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Age Groups: senior | adult
Covered Countries GBR

No variant requirements are available.